Associate Professor Michael Izard

Clinical Associate Professor
Medicine, Northern Clinical School

Telephone 02 9458 8000
Fax 02 9458 8077

Map

Selected publications

Download citations: PDF RTF Endnote

Books

  • Izard, M., Cassels, B., Webb, D., Oliver, L., Letwin, H., Au-Yeung, D., Aerts, M., Duchesne, G., Drummond, R. (2008). Safety Guide for Radiation Protection in Radiotherapy. Australia: ARPANSA.

Journals

  • Izard, M., Morris, L., Wan, W., Martin, J. (2013). Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones. Brachytherapy, 12(6), 608-614. [More Information]
  • Hong, A., Fogarty, G., Izard, M. (2012). The Role of Radiation Therapy in the Management of Metastatic Melanoma in the Brain. International Journal of Surgical Oncology, 2012, 1-6. [More Information]
  • Seymour, E., Downes, S., Fogarty, G., Izard, M., Metcalfe, P. (2011). In vivo real-time dosimetric verification in high dose rate prostate brachytherapy. Medical Physics, 38(8), 4785-4794. [More Information]
  • Izard, M. (2010). Early management of prostate cancer. Australian Family Physician, 39, 61-62. [More Information]
  • Izard, M., Haddad, R., Fogarty, G., Rinks, A., Dobbins, T., Katelaris, P. (2006). Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. International Journal of Radiation: Oncology - Biology - Physics, 66(1), 38-47. [More Information]
  • Izard, M. (2005). RE: Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: report on a survey of radiotherapy centres by K-H Tai et al. Journal of Medical Imaging and Radiation Oncology, 49, 256-257. [More Information]
  • Vardy, J., Wong, E., Izard, M., Clifford, A., Clarke, S. (2002). Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anti-Cancer Drugs, 13(3), 327-330.

2013

  • Izard, M., Morris, L., Wan, W., Martin, J. (2013). Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones. Brachytherapy, 12(6), 608-614. [More Information]

2012

  • Hong, A., Fogarty, G., Izard, M. (2012). The Role of Radiation Therapy in the Management of Metastatic Melanoma in the Brain. International Journal of Surgical Oncology, 2012, 1-6. [More Information]

2011

  • Seymour, E., Downes, S., Fogarty, G., Izard, M., Metcalfe, P. (2011). In vivo real-time dosimetric verification in high dose rate prostate brachytherapy. Medical Physics, 38(8), 4785-4794. [More Information]

2010

  • Izard, M. (2010). Early management of prostate cancer. Australian Family Physician, 39, 61-62. [More Information]

2008

  • Izard, M., Cassels, B., Webb, D., Oliver, L., Letwin, H., Au-Yeung, D., Aerts, M., Duchesne, G., Drummond, R. (2008). Safety Guide for Radiation Protection in Radiotherapy. Australia: ARPANSA.

2006

  • Izard, M., Haddad, R., Fogarty, G., Rinks, A., Dobbins, T., Katelaris, P. (2006). Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. International Journal of Radiation: Oncology - Biology - Physics, 66(1), 38-47. [More Information]

2005

  • Izard, M. (2005). RE: Three-dimensional conformal radiotherapy in the treatment of prostate cancer in Australia and New Zealand: report on a survey of radiotherapy centres by K-H Tai et al. Journal of Medical Imaging and Radiation Oncology, 49, 256-257. [More Information]

2002

  • Vardy, J., Wong, E., Izard, M., Clifford, A., Clarke, S. (2002). Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anti-Cancer Drugs, 13(3), 327-330.

To update your profile click here. For support on your academic profile contact .